Mkts

Cullinan Therapeutics, Inc.

NASDAQ: CGEM
$12.93-1.07 (-7.64%)
As of Oct 16, 4:00 PM ET

Key statistics

Day range
12.8113.91
52-week range
6.7323.19
Today
Open13.91
Previous close12.93
Volume—
Valuation
Market cap832.11M
P/E ratio—
EPS (TTM)-3.41
Income & risk
Dividend / yield—
Beta-0.01
Avg volume978.2K
Discussion

CGEM News

Stories mentioning CGEM from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue
Cost of Goods Sold
Gross Profit0.000.000.000.000.000.000.000.00
Operating Expenses
Research & Development42,12342,94541,96861,03041,45940,49235,50636,259
Sales General & Admin
Total Operating Expenses53,69755,25955,59575,79854,99655,04848,85550,027
Operating Income (Loss)(53,697)(55,259)(55,595)(75,798)(54,996)(55,048)(48,855)(50,027)
Interest Income4,0984,6155,0935,9246,5807,5128,3848,071
Interest Expense
Other Expense(62.00)(69.00)(108.00)(181.00)(85.00)6.00(89.00)(72.00)
Pretax Income
Tax Provision
Net Income (Loss)(50,713)(50,610)(70,055)(48,501)(47,647)(40,560)(42,028)
Earnings Per Share (Basic)(0.69)(0.75)
Earnings Per Share (Diluted)(0.69)(0.75)
Weighted Average Shares Outstanding (Basic)58,33755,052
Weighted Average Shares Outstanding (Diluted)58,33755,052

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About CGEM

Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is a stock listed on the Nasdaq Stock Market under the ticker symbol CGEM. It last traded at $12.93 (Oct 16, 2026, 4:00 PM ET), down 7.6% on the day. That gives Cullinan Therapeutics a market capitalisation of $832.1M.

Over the past 52 weeks CGEM has traded between $6.73 and $23.19.

For the quarter ended Dec 31, 2025 it reported a net loss of $50.7M.

Last 4 quarters
Quarter endedRevenueNet income
Dec 31, 2025—-$50.7M
Sep 30, 2025—-$50.6M
Jun 30, 2025—-$70.1M
Mar 31, 2025—-$48.5M

From Cullinan Therapeutics’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…